Open wa­ter: NI­BR chief Jay Brad­ner part­ners with UC Berke­ley on pro­tein drug re­search in­sti­tute

Al­most ex­act­ly two years to the day since he was named head of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, Jay Brad­ner is cel­e­brat­ing the an­niver­sary with a new col­lab­o­ra­tion with top in­ves­ti­ga­tors at UC Berke­ley fo­cus­ing on pro­tein drug re­search.

In­spired by the land­mark al­liance with Penn that re­cent­ly led to the ap­proval of the world’s first CAR-T drug, Brad­ner is div­ing deep in­to a field he was al­ready im­mersed in as a re­searcher at Dana-Far­ber. In do­ing so he plans to take co­va­lent bind­ing to a whole new lev­el in search of new break­throughs that can start hit­ting some cur­rent­ly “un­drug­gable” tar­gets.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN